Understanding Saxenda & Vision Loss Lawsuits
Saxenda contains liraglutide, a GLP-1 receptor agonist that was first approved by the U.S. Food and Drug Administration in 2014 to help adults manage chronic weight problems. The drug mimics a natural hormone that curbs appetite and slows digestion, which is why it's prescribed for type 2 diabetes.
In recent years, doctors and researchers have raised concerns about non-arteritic anterior ischemic optic neuropathy (NAION) — a sudden loss of blood flow to the optic nerve that can cause permanent vision loss in one eye, often without any warning.
Patients with type 2 diabetes who are prescribed liraglutide have a 179% higher likelihood of developing NAION than those prescribed other diabetes medications, according to Epic Research.
Saxenda vision loss lawsuits generally allege that Novo Nordisk:
- Knew or should have known about the potential link between liraglutide and NAION
- Failed to adequately warn doctors and patients of this risk on the drug's label
- Continued to market Saxenda for weight loss without disclosing what researchers were finding
- Put profits ahead of patient safety by downplaying a condition with no available cure
A 2024 study published in JAMA Ophthalmology found that patients prescribed semaglutide, a related GLP-1 drug, faced a significantly higher risk of developing NAION than patients on other weight-loss medications — with the highest risk occurring within the first year of starting treatment.
At Sokolove Law, we’ve secured more than $1.6 Billion total for patients harmed by dangerous drugs and medical devices. Let our team fight for you.
Get the Help You Deserve
We’ve helped thousands of families hold powerful pharmaceutical companies accountable. Find out if you may be able to file a Saxenda lawsuit.
Who May Be Eligible to File a GLP-1 NAION Lawsuit?
Vision loss from NAION often happens upon waking, with no pain and very little warning. Many patients describe noticing a dark spot or blurred area in their field of vision that simply doesn't go away.
Because there's currently no proven treatment to reverse the damage, the impact on a person's daily life, independence, and ability to work can be significant and lasting.
You may be eligible to file a GLP-1 NAION lawsuit if you or a loved one:
- Used Saxenda or a similar GLP-1 drug for weight management
- Experienced sudden, painless vision loss or blurred vision, typically in one eye
- Were diagnosed by an eye doctor with NAION or a related optic nerve injury
- Had no prior history of NAION before starting the medication
GLP-1 NAION lawsuits may involve semaglutide drugs like Ozempic®, Wegovy®, and Rybelsus®, tirzepatide drugs like Mounjaro® and Zepbound®, and liraglutide drugs like Saxenda, as well as the dulaglutide drug Trulicity®.
State statutes of limitations place strict deadlines on how long you have to file a liraglutide NAION lawsuit, so it's important to reach out as soon as possible if you believe Saxenda or another GLP-1 medication may have played a role in your vision loss.
Call (800) 995-1212 now for a free, no-obligation case review. There's no cost to find out if you may have a claim.
Saxenda & NAION Vision Problems
NAION occurs when blood flow to the front portion of the optic nerve is suddenly reduced or cut off, starving nerve cells of oxygen. Considered an "eye stroke," NAION is the leading cause of sudden optic nerve-related vision loss in adults over 50, affecting thousands of Americans every year.
Common Saxenda NAION symptoms include:
- Sudden, painless vision loss in one eye, often noticed immediately after waking up
- A dark or blurry patch in part of the visual field
- Difficulty noticing the loss at first, especially if the unaffected eye compensates
- No improvement, or only partial improvement, in the weeks and months that follow
There is currently no FDA-approved treatment that can reverse vision loss once NAION occurs, which is why early legal guidance matters: Families need real information about what their diagnosis means for the future, not just for their health, but for their financial security.
"People are just waking up and developing this [vision] condition. They wake, and they totally can't see. A lot of them lose their peripheral vision. They could lose total vision. I have one client who lost it in both eyes."
– Saxenda Lawyer
What Are Some Saxenda Side Effects?
Beyond NAION, Saxenda and other liraglutide medications carry a range of potential side effects that patients should be aware of.
Health issues that have been associated with Saxenda include:
- Vision loss caused by non-arteritic anterior ischemic optic neuropathy (NAION)
- Gastroparesis (stomach paralysis) and delayed gastric emptying
- Gallbladder disease, including gallstones
- Kidney injury related to severe nausea, vomiting, or diarrhea
- Pancreatitis
- Severe hypoglycemia, particularly when combined with other diabetes medications
- Thyroid C-cell tumors, which is the subject of a boxed warning on Saxenda's FDA label
While many of these risks are disclosed in Saxenda's prescribing information, lawsuits allege that the connection to NAION was not communicated clearly enough for patients to make a fully informed decision before starting treatment.
How to File a Saxenda NAION Lawsuit
Taking legal action after a vision loss diagnosis can feel overwhelming, especially while you're still adjusting to the change in your daily life. At Sokolove Law, we aim to take that burden off your shoulders.
Our Saxenda attorneys may be able to help:
- Confirm your eligibility during a free case review
- Gather your medical records, ophthalmology reports, and treatment history to support your claim
- File your Saxenda NAION lawsuit within the deadlines set by your state's statute of limitations
- Negotiate with Novo Nordisk and any other responsible parties on your behalf
- Represent you in court if a Saxenda settlement can't be reached through negotiation
You focus on adjusting to life after your diagnosis. We'll focus on building the strongest possible case for you and fighting for compensation for your medical bills, lost wages, and more.
Why Choose Our Saxenda Lawsuit Lawyers?
Facing a pharmaceutical giant like Novo Nordisk on your own is daunting. Their legal teams are large, experienced, and well-funded — which is exactly why so many families turn to firms like ours for help leveling the playing field.
Why do families choose Sokolove Law for their Saxenda claims?
- 45+ Years in Practice: Since 1979, our firm has represented clients across the country in cases involving dangerous drugs, defective products, and corporate negligence.
- Over $1.6 Billion Recovered: We've secured significant compensation for clients harmed by pharmaceutical products and medical devices.
- A Nationwide Presence: With attorneys and offices across the U.S., we can take on Saxenda cases in all 50 states.
- Zero Upfront Costs: We handle Saxenda cases on a contingency-fee basis, meaning you pay nothing unless your case is successful.
If you suffered Saxenda vision changes, you deserve a legal team in your corner who will treat your case with the seriousness it deserves.
Saxenda Lawsuit Updates 2026
In December 2025, the U.S. Judicial Panel on Multidistrict Litigation ordered the creation of MDL No. 3163 specifically for NAION vision loss claims tied to GLP-1 drugs, separating them from the older gastrointestinal injury litigation.
The panel determined that vision loss is a fundamentally different type of injury that deserved its own coordinated proceeding, even though many of the underlying legal and scientific questions overlap.
Key facts about the Saxenda and GLP-1 NAION litigation:
- MDL name: In re: Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) Non-Arteritic Anterior Ischemic Optic Neuropathy Products Liability Litigation (MDL No. 3163)
- Court: U.S. District Court for the Eastern District of Pennsylvania
- Judge: The Honorable Karen S. Marston
- Defendants: Novo Nordisk and Eli Lilly and Company
- Related litigation: MDL No. 3094, the separate, earlier-established GLP-1 litigation covering gastrointestinal injuries like gastroparesis, which is also overseen by Judge Marston
The NAION-specific litigation remains in its early stages, with no trials or settlements reached yet. Coordinated pretrial proceedings, including information sharing and the review of scientific evidence, are ongoing under Judge Marston's supervision.
Saxenda lawsuits involving NAION vision loss have moved quickly through the federal court system as more research has come to light.
Federal Court Creates Saxenda Vision Loss MDL
In December 2025, a federal judicial panel created a new multidistrict litigation to handle lawsuits alleging that GLP-1 medications caused patients to develop non-arteritic anterior ischemic optic neuropathy (NAION), a rare eye condition that can result in permanent vision loss.
The new MDL includes claims involving Novo Nordisk's Ozempic, Saxenda, and Wegovy, as well as Eli Lilly's Trulicity. The judicial panel concluded that the vision loss lawsuits involve different medical evidence and legal issues than the existing gastroparesis litigation.
At the time the MDL was created, 30 federal lawsuits and more than 40 state court cases had been filed, with additional claims expected as the litigation continues.
Study Links Saxenda to Vision Loss
A 2024 study published in JAMA Ophthalmology examined health records from 16,827 patients and found an association between semaglutide use and an increased risk of NAION.
Researchers reported that patients prescribed semaglutide for type 2 diabetes or obesity developed NAION more often than those taking other medications.
Although the study focused on semaglutide and not liraglutide, the active ingredient in Saxenda, it prompted broader interest in whether GLP-1 receptor agonists may be associated with vision complications.
Filing Saxenda Lawsuits for Families Nationwide
Vision loss changes everything — from the ability to drive, to work, to live independently the way you once did. If a medication you trusted contributed to that loss, you should have the right to hold the manufacturer accountable.
At Sokolove Law, we've helped families harmed by corporate wrongdoing and negligence get justice, securing more than $10.3 Billion total nationwide.
A Saxenda lawsuit may help you:
- Hold Novo Nordisk responsible for failing to adequately warn about NAION
- Recover compensation for medical bills, lost income, and ongoing care needs
- Seek damages for the pain, suffering, and lifestyle changes caused by permanent vision loss
- Bring greater transparency to the risks associated with GLP-1 medications
See if you have a case for free. Call (800) 995-1212 or fill out our contact form to speak with our team. It costs nothing to find out where you stand.
Liraglutide Lawsuit FAQs
Who can file a Saxenda lawsuit?
You may be eligible to file a Saxenda lawsuit if you used Saxenda or another GLP-1 medication and were later diagnosed with NAION or another serious optic nerve injury, especially if you had no prior history of vision problems before starting the medication.
A documented medical diagnosis is generally required to pursue a claim. Contact Sokolove Law for a free case review to find out if your situation may qualify.
Is there a Saxenda class action lawsuit?
There is currently no Saxenda class action lawsuit. Instead, individual claims involving Saxenda and other GLP-1 drugs linked to NAION have been consolidated into a federal multidistrict litigation, MDL No. 3163, in the Eastern District of Pennsylvania.
This allows similar cases to move through pretrial proceedings together while each victim still pursues their own individual claim and compensation.
As of this date, at least 110 Saxenda NAION claims have been filed by families.
Has Novo Nordisk settled any Saxenda NAION lawsuits?
Not yet. As of this date, the GLP-1 NAION litigation, including claims involving Saxenda, remains in the early stages of pretrial proceedings. No trials or global Saxenda settlements have been reached. Victims and their attorneys continue to gather scientific and medical evidence as the case moves forward.
What other health issues are associated with Saxenda?
Beyond NAION, Saxenda has been linked to gastrointestinal complications like gastroparesis, pancreatitis, gallbladder disease, kidney problems related to severe dehydration, and thyroid C-cell tumors — the subject of a boxed warning on Saxenda's official prescribing information.
If you experienced any of these health issues after using Saxenda, contact our team to discuss your potential options.
Can Saxenda affect your vision?
Saxenda contains liraglutide, a GLP-1 receptor agonist. Research published in recent years focused on the closely related drug semaglutide, has identified a possible association between GLP-1 medications and NAION, a sudden and often permanent loss of vision caused by reduced blood flow to the optic nerve.
Lawsuits allege that Novo Nordisk, the drug's manufacturer, knew or should have known about this risk and failed to properly warn patients of Saxenda eye problems before they started treatment.
Does Saxenda cause blurred vision?
Blurred vision is a reported side effect of Saxenda. In some cases, Saxenda blurred vision could also be a sign of a more serious eye condition like NAION and should be evaluated by a health care provider.
How much does it cost to hire a Saxenda lawyer?
At Sokolove Law, there is no upfront cost to work with our Saxenda attorneys. We operate on a contingency-fee basis, which means we only get paid if your case results in compensation. This removes the financial barrier that might otherwise keep injured patients from pursuing the justice they deserve.
Can NAION be treated or reversed?
Currently, no. There is no FDA-approved treatment that reliably reverses vision loss caused by NAION. Some patients experience minor improvement in the weeks following diagnosis, but for many, the vision loss is permanent.
What's the difference between Saxenda, Ozempic, and Wegovy?
All of these medications are GLP-1 receptor agonists, but they're not identical. Ozempic and Wegovy both contain semaglutide and are manufactured by Novo Nordisk; Wegovy is approved specifically for weight management, while Ozempic is approved to treat type 2 diabetes.
Saxenda contains liraglutide and is also made by Novo Nordisk. Saxenda is approved for weight management.
Despite these differences, all four drugs belong to the same broader class of medications now under scrutiny for a possible connection to NAION.
